U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. RX South DBA RX3 Compounding Pharmacy LLC - 440735 - 06/26/2019
  1. Warning Letters

CLOSEOUT LETTER

RX South DBA RX3 Compounding Pharmacy LLC MARCS-CMS 440735 —

Product:
Drugs
Recipient:
Recipient Name
Christopher K. Currin, R.Ph.
Recipient Title
Co-Owner
RX South DBA RX3 Compounding Pharmacy LLC

12230 Iron Bridge Rd.
Suite C
Chester, VA 23831-1534
United States

Issuing Office:
Center for Drug Evaluation and Research

10 Waterview Blvd.
3rd FL
Parsippany, NJ 07054
United States

(973) 331-4900

Dear Mr. Currin:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter dated October 23, 2014. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Craig Swanson
Acting Program Division Director/District Director
Office of Manufacturing Quality Operations
Division I/New Jersey District

Back to Top